Transcriptional and epigenetic events underpinning Navacim-Induced TR1 cell formation and expansion
More than 100 autoimmune diseases have complex immune responses to autoantigens. Nanoparticles coated with autoimmune-disease-relevant peptide-major histocompatibility complexes (Navacims) have the potential to halt and cure autoimmune disease by restoring immune tolerance without compromising normal immunity to infections and cancer. They are currently the only technology that can activate internal generation of disease-specific regulatory T …